Tera Therapeutics
Biotechnology company developing large-scale "Gene Writing" therapies for repairing deleterious human gene mutations using novel transposon and retrotransposon-based approaches.
Notes
Tera Therapeutics is a biotechnology company developing large-scale "Gene Writing" therapies for repairing deleterious human gene mutations. The company uses novel transposon and retrotransposon-based approaches that can insert large genetic payloads into the genome.
Unlike CRISPR-based gene editing which primarily makes small changes or disrupts genes, Tera's gene writing approach can insert complete functional genes into the genome. This capability is particularly important for:
- Diseases caused by large gene deletions
- Conditions requiring insertion of full-length genes
- Applications where precise gene addition is needed
The technology offers potential advantages over viral vector-based gene therapy, including the ability to integrate larger payloads and potentially more precise integration.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Gene Writing technology platform
- Transposon and retrotransposon-based approaches
- Large-scale genetic payload insertion
- Gene repair applications
- Boston, Massachusetts headquarters
- Founded in 2021
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |